Its dividend: The stock recently yielded a whopping 7.3%. That's hard to beat and will generate around $730 for every $10,000 ...

BMY is looking to expand its pipeline/portfolio as the legacy portfolio is being adversely impacted due to continued generic ...

Pfizer reported a strong sales performance for its antifungal drug Cresemba in the Asia Pacific and China, thanks to a ...

Pfizer Inc. closed 26.70% short of its 52-week high of $31.54, which the company achieved on July 30th.

Pfizer (NYSE:PFE) announced robust sales for the antifungal drug Cresemba in partnership with Basilea Pharmaceutica Ltd, ...

Pfizer’s stock has dropped 25% from its recent high, raising questions about whether it's a buy at $23. Pipeline failures and ...

Despite recent declines, we believe Pfizer stock is a compelling buy right now, with its current price of around $23 likely ...

Pfizer halted its oral obesity drug, danuglipron, in April 2025 due to liver injury concerns, a major pipeline setback. Find ...

Pfizer (NYSE:PFE) recently presented groundbreaking findings in cancer research, particularly the first-in-human Phase 1 clinical study of the innovative MesoC2 drug at the ASCO Annual Meeting, and ...

Detailed price information for Walt Disney Company (DIS-N) from The Globe and Mail including charting and trades.

In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against other cheap NYSE stocks. On March 26, Jack Caffrey of JPMorgan Asset Management provided an analysis of ...